Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy
✍ Scribed by Alyssa T. Reddy; Anna J. Janss; Peter C. Phillips; Heidi L. Weiss; Roger J. Packer
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 87 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
The outcome of a child with a primitive neuroectodermal tumors arising supratentorially (SPNET) is not well characterized and may differ from the outcome of a patient with a histologically similar cerebellar tumor (medulloblastoma [MB]). Recently, 5-year progression free survival rates as high as 80% have been reported for children with MB treated with craniospinal radiation (CRT) and chemotherapy including cisplatin, lomustine (CCNU), and vincristine (VCR).
METHODS.
The authors reviewed the outcome of 22 consecutive patients age 3 years and older (mean age, 10 years; range, 3-18 years) with SPNET who were treated at the study institutions between 1981 and 1996. Tumor location included was 13 pineal, 6 cortical, and 3 thalamic or suprasellar. Five patients had disease dissemination at diagnosis. All patients underwent surgery and staging, followed by CRT and chemotherapy with cisplatin, CCNU, and VCR.